Cargando…

Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system in young adults. Over time, the disease progresses and, with accumulating disability, symptoms such as spasticity may occur. Although several treatment options are available, some...

Descripción completa

Detalles Bibliográficos
Autores principales: Rommer, P. S., Kamin, F., Petzold, A., Tumani, H., Abu-Mugheisib, M., Koehler, W., Hoffmann, F., Winkelmann, A., Benecke, R., Zettl, U. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245486/
https://www.ncbi.nlm.nih.gov/pubmed/24986188
http://dx.doi.org/10.1007/s40291-014-0114-3
_version_ 1782346358454222848
author Rommer, P. S.
Kamin, F.
Petzold, A.
Tumani, H.
Abu-Mugheisib, M.
Koehler, W.
Hoffmann, F.
Winkelmann, A.
Benecke, R.
Zettl, U. K.
author_facet Rommer, P. S.
Kamin, F.
Petzold, A.
Tumani, H.
Abu-Mugheisib, M.
Koehler, W.
Hoffmann, F.
Winkelmann, A.
Benecke, R.
Zettl, U. K.
author_sort Rommer, P. S.
collection PubMed
description BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system in young adults. Over time, the disease progresses and, with accumulating disability, symptoms such as spasticity may occur. Although several treatment options are available, some patients may not respond to first-line therapeutics. However, some of these patients may benefit from intrathecally administered triamcinolone-acetonide (TCA), a derivative of glucocorticosteroids (GCS). GCS may have neurotoxic effects, and cell apoptosis may occur. The aim of this study was to investigate the effects of TCA on biomarkers in the cerebrospinal fluid (CSF) suggestive of neurodegeneration. METHODS: In order to assess neurotoxic effects of TCA, neurofilament heavy-chain (NfH)(SMI35), tau protein, and S-100B protein levels were determined before and during treatment with TCA in 54 patients with primary progressive MS, as well as relapsing MS (relapsing–remitting and secondary progressive MS). RESULTS: NfH(SMI35) levels in the CSF of patients treated with TCA intrathecally did not increase significantly during the treatment cycle (p = 0.068). After application of TCA, tau protein levels were increased significantly at day 4 (p = 0.03) and at day 8 (p ≤ 0.001). S-100B protein levels decreased significantly (p ≤ 0.05) during treatment with TCA. CONCLUSION: NfH(SMI35) levels did not change significantly; however, tau protein levels did increase significantly within the reference range. Taking these findings together, the long-term effects of TCA on NfH(SMI35) and tau protein levels need to be investigated further to understand whether levels of both biomarkers will change over repeated TCA applications. Interestingly, S-100B protein levels decreased significantly during the first applications, which may have represented reduced astrocytic activity during TCA treatment.
format Online
Article
Text
id pubmed-4245486
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-42454862014-12-03 Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients Rommer, P. S. Kamin, F. Petzold, A. Tumani, H. Abu-Mugheisib, M. Koehler, W. Hoffmann, F. Winkelmann, A. Benecke, R. Zettl, U. K. Mol Diagn Ther Short Communication BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system in young adults. Over time, the disease progresses and, with accumulating disability, symptoms such as spasticity may occur. Although several treatment options are available, some patients may not respond to first-line therapeutics. However, some of these patients may benefit from intrathecally administered triamcinolone-acetonide (TCA), a derivative of glucocorticosteroids (GCS). GCS may have neurotoxic effects, and cell apoptosis may occur. The aim of this study was to investigate the effects of TCA on biomarkers in the cerebrospinal fluid (CSF) suggestive of neurodegeneration. METHODS: In order to assess neurotoxic effects of TCA, neurofilament heavy-chain (NfH)(SMI35), tau protein, and S-100B protein levels were determined before and during treatment with TCA in 54 patients with primary progressive MS, as well as relapsing MS (relapsing–remitting and secondary progressive MS). RESULTS: NfH(SMI35) levels in the CSF of patients treated with TCA intrathecally did not increase significantly during the treatment cycle (p = 0.068). After application of TCA, tau protein levels were increased significantly at day 4 (p = 0.03) and at day 8 (p ≤ 0.001). S-100B protein levels decreased significantly (p ≤ 0.05) during treatment with TCA. CONCLUSION: NfH(SMI35) levels did not change significantly; however, tau protein levels did increase significantly within the reference range. Taking these findings together, the long-term effects of TCA on NfH(SMI35) and tau protein levels need to be investigated further to understand whether levels of both biomarkers will change over repeated TCA applications. Interestingly, S-100B protein levels decreased significantly during the first applications, which may have represented reduced astrocytic activity during TCA treatment. Springer International Publishing 2014-07-02 2014 /pmc/articles/PMC4245486/ /pubmed/24986188 http://dx.doi.org/10.1007/s40291-014-0114-3 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Short Communication
Rommer, P. S.
Kamin, F.
Petzold, A.
Tumani, H.
Abu-Mugheisib, M.
Koehler, W.
Hoffmann, F.
Winkelmann, A.
Benecke, R.
Zettl, U. K.
Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title_full Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title_fullStr Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title_full_unstemmed Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title_short Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
title_sort effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245486/
https://www.ncbi.nlm.nih.gov/pubmed/24986188
http://dx.doi.org/10.1007/s40291-014-0114-3
work_keys_str_mv AT rommerps effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT kaminf effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT petzolda effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT tumanih effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT abumugheisibm effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT koehlerw effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT hoffmannf effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT winkelmanna effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT benecker effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients
AT zettluk effectsofrepeatedintrathecaltriamcinoloneacetonideapplicationoncerebrospinalfluidbiomarkersofaxonaldamageandglialactivityinmultiplesclerosispatients